AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer

This research is an early-stage study, called a Phase I trial, investigating a new treatment named TG4070 for individuals diagnosed with non-small cell lung cancer. This is the very first time this new medicine is being given to people. The main goal at this stage is to understand how safe TG4070 is and how the body handles it. Doctors will also be looking to see what dose might be best for future studies. Because it's an early study, we don't know much about the medicine yet, but trials like this are a vital step in finding new and better ways to treat cancer. Participants will be carefully monitored throughout the study.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

Transgene

Enrolment target

Start

15 Jul 2025

Non-Small Cell Lung Cancer

What is this study about?

This study is investigating a new medication called TG4070 for people who have a type of lung cancer known as non-small cell lung cancer. It's an important early step in developing new treatments. This kind of study, called a Phase I trial, is usually the very first time a new medicine is given to humans. \n\nThe main aims of this study are to find out if TG4070 is safe for people to take, what side effects it might cause, and how the body processes the medication. Researchers will also be looking to see what dose of TG4070 might be the most effective and safest for people to receive in future, larger studies. \n\nEven though this is an early study and we don't yet know much about TG4070, trials like this are crucial for developing new and potentially better ways to treat serious illnesses like cancer. Every new treatment that is available today started with studies just like this one, carefully progressing to ensure they are safe and effective.

Key takeaways

This is an early-stage study of a new lung cancer drug, TG4070.
The main goal is to check the safety and how the drug works in the body.
Participants must be 18 or older; both men and women can join.
You will receive the new medicine and have regular health checks.
There are potential benefits and risks, which will be fully explained.
You can leave the study at any time without affecting your care.

Who may be eligible?

To join this study, people need to be at least 18 years old. Both men and women can take part. \n\nBecause this is an early study, there will be other health requirements too. For example, doctors will need to make sure your general health is good enough to take part and that the study medicine won't interfere with any other conditions or treatments you have. \n\nThe research team will review your medical information carefully to see if this study is suitable for you. It's important to remember that these details are broad, and the study doctors will go through all the specific requirements with you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have non-small cell lung cancer?
Are you able to attend regular hospital visits?
Are you willing to potentially try a new, experimental treatment?
Are you able to understand and agree to the study requirements?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would receive the new medicine, TG4070. Participation would involve regular visits to the hospital or clinic for check-ups. During these visits, the study team would perform various assessments, such as physical exams, blood tests, and scans, to monitor your health and how your body is reacting to the treatment. They would also keep a close eye on any side effects you might experience. These visits are essential to ensure your safety and to gather important information about the new medicine. The total duration of your participation in the study, including the treatment and any follow-up visits, would be explained in detail by the study team.

Potential risks and benefits

Taking part in any clinical trial involves both potential benefits and risks. A potential benefit of joining this study is that you would receive a new and experimental treatment that is not yet widely available, which might help your condition. However, because this is a new medicine, there could be unknown side effects or it might not work for you. The study team will explain all the known risks and side effects in detail. You are always free to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is a Phase I trial?

A Phase I trial is the very first time a new medicine is given to people. Its main purpose is to check if the medicine is safe and how the body handles it, rather than focusing on how well it works.

What is non-small cell lung cancer?

Non-small cell lung cancer is the most common type of lung cancer. It's a disease where abnormal cells grow in the lung tissue.

Will TG4070 cure my cancer?

It's too early to know. This study is mainly focused on safety. While some people might see benefits, its main goal is to understand the medicine better for future studies.

How long will the study last if I join?

The exact duration will depend on a few things, but the study team will explain the full timeline, including treatment and follow-up, during the consent process.

Can I continue my regular cancer treatment if I join?

The study team will need to review all your current medications and treatments to see if you can safely participate alongside them. This will be discussed in detail.